<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Neurobiol</journal-id><journal-id journal-id-type="iso-abbrev">Exp Neurobiol</journal-id><journal-id journal-id-type="publisher-id">EN</journal-id><journal-title-group><journal-title>Experimental Neurobiology</journal-title></journal-title-group><issn pub-type="ppub">1226-2560</issn><issn pub-type="epub">2093-8144</issn><publisher><publisher-name>The Korean Society for Brain and Neural Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4688327</article-id><article-id pub-id-type="doi">10.5607/en.2015.24.4.257</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article: Autism Spectrum Disorders</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Genetics of Autism Spectrum Disorder: Current Status and Possible Clinical Applications </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yoo</surname><given-names>Heejeong</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Psychiatry, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea.</aff><author-notes><corresp>To whom correspondence should be addressed. TEL: 82-31-787-7436, FAX: 82-31-787-4058, <email>hjyoo@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2015</year></pub-date><volume>24</volume><issue>4</issue><fpage>257</fpage><lpage>272</lpage><history><date date-type="received"><day>26</day><month>10</month><year>2015</year></date><date date-type="rev-recd"><day>02</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>02</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>Copyright Â© Experimental Neurobiology 2015.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Autism spectrum disorder (ASD) is one of the most complex behavioral disorders with a strong genetic influence. </plain></SENT>
<SENT sid="2" pm="."><plain>The objectives of this article are to review the current status of genetic research in ASD, and to provide information regarding the potential candidate genes, mutations, and genetic loci possibly related to pathogenesis in ASD. </plain></SENT>
<SENT sid="3" pm="."><plain>Investigations on monogenic causes of ASD, candidate genes among common variants, rare de novo mutations, and copy number variations are reviewed. </plain></SENT>
<SENT sid="4" pm="."><plain>The current possible clinical applications of the genetic knowledge and their future possibilities are highlighted. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Autism spectrum disorder</kwd><kwd>Syndromic autism</kwd><kwd><italic>de novo</italic> mutations</kwd><kwd>Genetic diagnosis</kwd></kwd-group></SecTag><funding-group><award-group><funding-source country="KR"><institution-wrap><institution>Ministry of Health and Welfare</institution><institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/100008903</institution-id></institution-wrap></funding-source><award-id>A120029</award-id></award-group></funding-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="5" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="6" pm="."><plain>Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by very early onset of dysfunction in social communication and interaction, repetitive behavior, and limited interest. </plain></SENT>
<SENT sid="7" pm="."><plain>It is now believed that ASD is a result of complex gene-environment interactions, with strong and clear genetic influences. </plain></SENT>
<SENT sid="8" pm="."><plain>Studies of twin pairs, high-risk infant siblings, families, and populations have estimated concordance rates and segregation of the disorder within families. </plain></SENT>
<SENT sid="9" pm="."><plain>The concordance rate was reported as 60-70% in monozygous twins and as 5-30% in siblings; this is in agreement with a recent large prospective study revealing a recurrence rate of 18% in infant siblings and of 33% in multiplex families [12]. </plain></SENT>
<SENT sid="10" pm="."><plain>However, it is currently believed that over 50% of the risk of developing ASD is attributed to genetic variation [34]. </plain></SENT>
</text></p><p><text><SENT sid="11" pm="."><plain>Advances in genetic technologies, large cohort studies, and widespread database sharing have contributed to the discovery and validation of causative genes in ASD [5]. </plain></SENT>
<SENT sid="12" pm="."><plain>Knowledge from genetic studies of ASD also provides insight into other neurodevelopmental disorders, as ASD shares both behavioral characteristics and endophenotypes. </plain></SENT>
<SENT sid="13" pm="."><plain>However, ASD is one of the most heterogeneous neurodevelopmental disorders, with great variation observed in behavioral manifestations and cognitive profiles, which makes determination of the single most important genetic risk factor extremely difficult. </plain></SENT>
</text></p><p><text><SENT sid="14" pm="."><plain>Identifying biomarkers has been one of the primary goals of biological research of ASD, and current research efforts are directed predominantly toward the identification of markers for risk and early diagnosis [6]. </plain></SENT>
<SENT sid="15" pm="."><plain>There have been intense research efforts to identify the genetic basis of ASD, with an assumption that the genetic markers can be utilized as essential biomarkers in the diagnosis of, and the development of pharmacological treatments for, ASD. </plain></SENT>
<SENT sid="16" pm="."><plain>The objective of this paper is to review the current knowledge of genetic variations in ASD, and its role in the identification of genetic biomarkers of ASD for diagnostic and therapeutic purposes. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="17" pm="."><plain>GENETIC VARIANTS </plain></SENT>
</text></title><sec><title><text><SENT sid="18" pm="."><plain>Common variants </plain></SENT>
</text></title><p><text><SENT sid="19" pm="."><plain>The genetic architecture of ASD is diverse in frequency (common vs. rare variation), mode of inheritance (inherited vs. de novo variation), type of variation (single nucleotide, indel, or copy number variation [CNV]) and mode of action (dominant, recessive, or additive) [37]. </plain></SENT>
<SENT sid="20" pm="."><plain>Common variation refers to genetic variation from the reference genome, which is present in &gt;1% of the population. </plain></SENT>
<SENT sid="21" pm="."><plain>Common variants with small effects are thought to act additively in the development of complex traits in ASD [8]. </plain></SENT>
<SENT sid="22" pm="."><plain>One recent investigation reported that the liability of ASD is mostly attributed to common variation in the genetic architecture, and that rare de novo mutations contribute to individual liability (49% of common inherited variants, 3% of de novo, 3% of rare inherited variants, and 41% of unaccounted) [7]. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Confirmation of the most specific, consistently replicated, and highly effective common variants involved in the pathogenesis of ASD is another issue. </plain></SENT>
<SENT sid="24" pm="."><plain>The first molecular genetic studies of autism were candidate gene association studies that aimed to discover common genetic variants in the form of single-nucleotide polymorphisms (SNPs). </plain></SENT>
<SENT sid="25" pm="."><plain>However, a large disadvantage of this is that it requires existing physiological, biochemical, or functional knowledge, which is either finite or unavailable [9]. </plain></SENT>
<SENT sid="26" pm="."><plain>These investigations have been hindered by inadequate sample sizes and sparse genotyping, resulting in a lack of reproducible markers except for a few plausible genes [910]. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>The most consistently reported genes among the common variants include the gamma-aminobutyric acid (GABA) A receptor, beta 3 (GABRB3); oxytocin receptor (OXTR); reelin (RELN); serotonin transporter (SLC6A4); N-methyl-D-aspartate receptor (NMDA; GRIN2B); arginine vasopressin receptor 1A (AVPR1A); engrailed homeobox 2 (EN2); integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61; ITGB3); met proto-oncogene (hepatocyte growth factor receptor; MET); and contactin-associated protein-like 2 (CNTCAP2) genes [111213141516171819202122]. GABRB3, which is localized to chromosome 15q11-q13 and is involved in genome instability, gene expression, imprinting, and recombination, was investigated in the first era of ASD genetic research [1323]. </plain></SENT>
<SENT sid="28" pm="."><plain>This region became a major subject of attention because deletion of this locus is related to monogenic causes of ASD, Prader-Willi syndrome, and Algelman's syndrome, and because GABA may be a pharmacological therapeutic target [132425]. </plain></SENT>
<SENT sid="29" pm="."><plain>Oxytocin acts as a neuromodulator in the central nervous system, and induces social/affective bonding in animal models. </plain></SENT>
<SENT sid="30" pm="."><plain>The OXTR is a promising biomarker candidate, due to its genetic variants, functions on behavior, and positive results in human clinical trials [172627]. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>However, these candidate gene studies also revealed that common variation has a weak effect when individual SNPs are investigated. </plain></SENT>
<SENT sid="32" pm="."><plain>A genome-wide association study (GWAS) avoids the need for a priori hypotheses for the primary cause of illness, and is a more appropriate approach for genetic studies of complex disorders such as autism [10]. </plain></SENT>
<SENT sid="33" pm="."><plain>GWASs have been applied to psychiatric disorders with complex phenotypes, and several variants have been reported [28]. </plain></SENT>
<SENT sid="34" pm="."><plain>Several GWASs have been conducted for ASD, and a few well-designed studies reported that common genetic variants on 5p14.1 and 5p15 were highlighted and replicated in two independent samples, each carrying a small increased risk (OR 1.2) or protective effect (OR 0.6) [293031]. </plain></SENT>
<SENT sid="35" pm="."><plain>A significant association was observed with the CDH9 and CDH10 genes, but replications of this association was inconsistent [2930313233]. </plain></SENT>
<SENT sid="36" pm="."><plain>Several studies identified significant SNP markers that were replicated in two or more independent samples and were associated with specific phenotypes of ASD, but the effect sizes were relatively small [29303132333435]. </plain></SENT>
<SENT sid="37" pm="."><plain>However, significant genome-wide results were not consistently reproduced across studies and ethnicities [3335]. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>Those inconsistencies can be attributed to the phenotypic heterogeneity of ASD and to relatively small sample sizes. </plain></SENT>
<SENT sid="39" pm="."><plain>Researchers attempted to decrease phenotypic heterogeneity by subphenotyping or using quantitative phenotypes, but this was unsuccessful in enhancing the substantial power of GWAS, resulting in the necessity of very large sample sizes, such as 50,000 individuals [53334]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="40" pm="."><plain>Rare variants and monogenic autism </plain></SENT>
</text></title><p><text><SENT sid="41" pm="."><plain>Rare variation is genetic variation that is present in the population at a frequency of â¤1%. </plain></SENT>
<SENT sid="42" pm="."><plain>ASD can be expressed as the behavioral manifestation of known genetic syndromes, called syndromic autism, as opposed to idiopathic autism, which does not have known genetic causes. </plain></SENT>
<SENT sid="43" pm="."><plain>Syndromic autism often has dysmorphic features characterized by the genetic syndrome it belongs to and equal male:female ratios, unlike idiopathic autism, which occurs 4-5 times more frequently in males than in females [36]. </plain></SENT>
<SENT sid="44" pm="."><plain>Single-gene disorders, including fragile X (mutations in FMR1), tuberous sclerosis complex (mutations in TSC1 and TSC2), Dup15q syndrome, deletions in the 16p11.2 region, Rett syndrome (mutation in MeCP2), and neurofibromatosis (mutations in NF1), are detected in 3-5% of subjects with ASD, and are well-known as having an ASD phenotype as well as comorbid intellectual disabilities and epilepsy [37]. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>Recent development of whole-exome sequencing (WES) techniques has revealed that more than 25% of individuals with ASD have identifiable, causative, and protein-disrupting rare genetic mutations [5]. </plain></SENT>
<SENT sid="46" pm="."><plain>However, single mutations account for no more than 1% of cases, mainly due to phenotypic heterogeneity and variable penetrance. </plain></SENT>
<SENT sid="47" pm="."><plain>Though the prevalence is not strikingly high, syndromic autism helps to understand core deficits of ASD as one of the phenotypes that specific genetic mutations carry, and acts as a gateway to explore the genetic etiology of ASD. </plain></SENT>
<SENT sid="48" pm="."><plain>The representative examples of monogenic autism and their clinical implications are summarized in Table 1. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="49" pm="."><plain>Copy number variation </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>Copy number variants (CNVs) are variations (duplication or deletion) in chromosomal structure of greater than 1,000 nucleotides, usually a section of DNA with a length from 1 kb to several Mb. </plain></SENT>
<SENT sid="51" pm="."><plain>CNVs can be either common or rare, transmitted or de novo, and are widely distributed in human genome, accounting for a substantial proportion of genetic variation [538]. </plain></SENT>
<SENT sid="52" pm="."><plain>Studies have revealed an increased frequency of CNVs in individuals with ASD compared to normal controls and several de novo CNVs in children with autism, suggesting excessive genomic instability. </plain></SENT>
<SENT sid="53" pm="."><plain>The frequency of de novo CNVs in ASD has been reported as 3-19% in ASD from simplex and multiplex families, compared to approximately 1% in healthy controls [394041]. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>Genomic imbalances associated with ASD are classified as recurrent and nonrecurrent events. </plain></SENT>
<SENT sid="55" pm="."><plain>Recurrent events are non-allelic homologous recombination, with reciprocal dosage imbalances (deletion and duplication) in different individuals [42]. </plain></SENT>
<SENT sid="56" pm="."><plain>Notable examples of recurrent CNVs are microdeletions and duplications in chromosome 1q21, 15q13, and 16p11.2, and microdeletion syndrome in chromosomes 2p15-2p16.1, 17p11.2, and 17q12 [43444546474849]. </plain></SENT>
<SENT sid="57" pm="."><plain>CNVs are associated with a wide range of phenotypic heterogeneity, including dysmorphic features, intellectual disabilities, language impairments, attention problems, hyperactivity, aggression and other behavioral problems, mood disorders, and schizophrenia, which implicates those variants might not be a specific cause of social disability in ASD [18]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="58" pm="."><plain>Synaptic genes </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>Of the genetic variations studied regarding ASD, the most consistently reported genetic abnormalities are mutations in synaptic genes, including neuroligins (NLGN), SH3 and multiple ankyrin repeat domains (SHANK), neurexin (NRXN) families, and contactin associated protein-like 2 (CNTNAP2) [50515253545556575859606162]. </plain></SENT>
<SENT sid="60" pm="."><plain>Mutations in synaptic genes are not specific to ASD, and are also found in other neuropsychiatric disorders, such as schizophrenia and Alzheimer's disease [6364]. </plain></SENT>
<SENT sid="61" pm="."><plain>However, as these neuropsychiatric conditions share common features with ASD, such as cognitive dysfunction, limited emotional expression, and lack of social reciprocity, synaptic dysfunction is still considered a common pathway of these major, chronic neuropsychiatric illnesses [518]. </plain></SENT>
</text></p><p><text><SENT sid="62" pm="."><plain>NLGNs are known to act as splice site-specific ligands for beta-neurexins and be involved in the formation and remodeling of central nervous system synapses (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene/54413">http://www.ncbi.nlm.nih.gov/gene/54413</ext-link>). </plain></SENT>
<SENT sid="63" pm="."><plain>The identification of a de novo, loss of function mutation in neuroligin 4, X-linked (NLGN4X) in an affected mother that was transmitted to two affected boys first suggested the possibility of synaptic dysfunction involvement in ASD [65]. </plain></SENT>
<SENT sid="64" pm="."><plain>This was followed by the identification of a single-base missense mutation of NLGN3 in another family [53]. </plain></SENT>
<SENT sid="65" pm="."><plain>These findings have been replicated in other studies, and NLGN3, NLGN4, and NLGN4Y were found to be possibly associated with ASD. </plain></SENT>
<SENT sid="66" pm="."><plain>However, mutation of those genes in ASD is relatively low (0.6-3.3%), and the clinical phenotypes and neurobiological characteristics of these mutations are also quite diverse, including ASD, intellectual disabilities, and Tourette syndrome, and inconsistent across ethnicities [5154556162]. </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain>A second family of genes possibly associated with ASD is the SHANK genes (SHANK1, SHANK2, and SHANK3), encoding synaptic proteins that may function as molecular scaffolds in the postsynaptic density of excitatory synapses (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene/22941">http://www.ncbi.nlm. nih.gov/gene/22941</ext-link>). SHANK3 is the most widely studied, but SHANK1 and SHANK2 are also implicated by de novo deletions observed in subjects with ASD [50575859]. </plain></SENT>
<SENT sid="68" pm="."><plain>Durant et al. (2007) reported eight non-synonymous mutations in ASD patients that were not present in healthy controls; rare de novo mutations in SHANK3 located in chromosome 22q13.3 were identified in probands and families with ASD in many studies [50]. </plain></SENT>
<SENT sid="69" pm="."><plain>Rare mutations and genomic deletions have been reported in different SHANK3 loci, with a frequency of 0.2-0.8% of probands in ASD [505766676869]. </plain></SENT>
<SENT sid="70" pm="."><plain>Mutations in SHANK3 are gaining attention, as they are related to Phelan-McDermid syndrome (PMS) and 22q13 deletion syndrome, and are one of the known genetic causes of ASD. </plain></SENT>
<SENT sid="71" pm="."><plain>PMS is characterized by autism or autistic-like behavior in more than 50% of subjects, and is accompanied by neurological deficits, including global developmental delay, moderate to severe intellectual impairment, absent or severely delayed speech, and neonatal hypotonia [59]. </plain></SENT>
</text></p><p><text><SENT sid="72" pm="."><plain>The transmission pattern of SHANK3 mutations is variable; inheritance from healthy parents and existence in unaffected siblings were reported [505767]. </plain></SENT>
<SENT sid="73" pm="."><plain>Recently, Nemirovsky et al. (2015) reported germline mosaicism for a heterozygous cytosine deletion in exon 21 of SHANK3 by whole-genome sequencing in three male siblings from a segregated family exhibiting phenotypes of severe intellectual disability, absence of language, autism spectrum symptoms, and epilepsy [58]. </plain></SENT>
<SENT sid="74" pm="."><plain>As with other potential candidates, the associated phenotypes of SHANK3 mutations are not specific for ASD, but SHANK3 is regarded as one of the potential causative genes and therapeutic targets of ASD, based on animal and cellular model studies. </plain></SENT>
</text></p><p><text><SENT sid="75" pm="."><plain>Other important synaptic genes are NRXN1, NRXN2 and NRXN3, encoding neuroligins. </plain></SENT>
<SENT sid="76" pm="."><plain>This trans-synaptic complex is required for efficient neurotransmission, and they are involved in the formation of synaptic contacts by interaction with neurexins [60]. </plain></SENT>
<SENT sid="77" pm="."><plain>Neuroligin aggregation is synaptogenic, but exhibits specificity: NLGN1, NLGN3 and NLGN4 link only to glutamatergic postsynaptic proteins, but NLGN2 links to both glutamatergic and GABAergic postsynaptic proteins [52]. </plain></SENT>
<SENT sid="78" pm="."><plain>In the earlier era of ASD genetic studies, CNVs were found to disrupt the locus containing NRXN1, but this was inconsistent, with a high unaffected carrier frequency of deletions [70717273]. </plain></SENT>
<SENT sid="79" pm="."><plain>More recently, there have been relatively large cohort studies that describe a higher rate of deletions in the NRXN1 region located in the probands of chromosome 2p16.3 associated with ASD, compared to healthy controls, with an overrepresentation of small-sized inverted repeats [7274]. </plain></SENT>
<SENT sid="80" pm="."><plain>Shared psychopathologies related to the deletions were developmental delays, speech delays, abnormal behaviors, including ASD, and some degree of dysmorphism [72]. </plain></SENT>
</text></p><p><text><SENT sid="81" pm="."><plain>CNTNAP2 is another candidate gene suggested to be associated with ASD by human and animal model studies. </plain></SENT>
<SENT sid="82" pm="."><plain>Family-based association studies identified a common variant (rs7794745) that was associated with increased risk of autism, and another study revealed an amino acid substitution in the CNTNAP2 protein in children with autism [757677]. </plain></SENT>
<SENT sid="83" pm="."><plain>Variation of the CNTNAP2 gene and age at first word, a language development phenotype, are both related to autism rather than to the diagnosis itself, and raises the implication that genetic variants of a quantitative phenotype of ASD interact with FOXP2 [75]. </plain></SENT>
<SENT sid="84" pm="."><plain>The functional relevance of CNTNAP2 genetic variants has been validated in animal models; CNTNAP2 (-/-) mice exhibited deficits in all three core behavioral deficits of ASD, as well as hyperactivity and epileptic seizures, and improved repetitive behavior of mutant mice [78]. </plain></SENT>
<SENT sid="85" pm="."><plain>A large-sized GWAS study failed to demonstrate a significant association of the marker noted in the previous studies, and no associations between rare heterogeneous mutations of CNTNAP2 and ASD were observed [2979]. </plain></SENT>
<SENT sid="86" pm="."><plain>However, a recent investigation revealed the possible involvement of novel functional variants of the 5'-promotor region, mediated by alterations in transcription-binding sites in subjects with ASD. CNTNAP2 is still regarded as one of the potential causative genes of ASD that warrants further research [80]. </plain></SENT>
</text></p><p><text><SENT sid="87" pm="."><plain>These findings indicate the possibility that ASD might be caused by abnormalities in synaptic plasticity, as indicated by proteins that play essential roles in synaptic development and modification. </plain></SENT>
<SENT sid="88" pm="."><plain>There is evidence that NRXN (presynaptic) and NLGN (postsynaptic) interact as synaptic adhesion molecules, providing mechanistic support in synaptic formation and maintenance [81]. </plain></SENT>
<SENT sid="89" pm="."><plain>Alternate splicing of NLGN controls selective binding with Î±- and Î²-NRXN, provides synaptic diversity, and regulates function. </plain></SENT>
<SENT sid="90" pm="."><plain>Alternate splicing also controls the variable interaction of NRXN with other postsynaptic ligands, such as in glutamatergic, GABA-ergic, and cholinergic synapses [8182]. </plain></SENT>
<SENT sid="91" pm="."><plain>The SHANK family includes postsynaptic scaffolding proteins, which link multiple receptor signaling complexes and the actin cytoskeleton that are essential for maintaining synaptic function [83]. </plain></SENT>
<SENT sid="92" pm="."><plain>SHANK3 directly and indirectly binds to CNTN and NLGNs and interacts with presynaptic glutamatergic receptors [8384]. </plain></SENT>
<SENT sid="93" pm="."><plain>The molecular function of CNTNAP2 is relatively unclear, but it is known to encode a neuronal transmembrane protein member of the NRXN superfamily that is involved in neural-glia interactions and clustering of potassium channels in myelinated axons (<ext-link ext-link-type="uri" xlink:href="http://www.omim.org/entry/604569">http://www.omim.org/entry/604569</ext-link>). </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>Overall, despite of low frequency of de novo mutations in affected individuals, inconsistencies in genetic analysis results, and phenotypic heterogeneity, synapse-related genes are crucial candidates of ASD, and provide baseline evidence for testing compounds that can enhance synaptogenesis for the treatment of the core symptoms of ASD [25]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="95" pm="."><plain>Genetic networks </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>For some of the identified genes, genetic pathways were identified at the cellular and molecular level based on genetic network analyses and genetic functional studies. </plain></SENT>
<SENT sid="97" pm="."><plain>Besides synaptic development and function mentioned in the previous section, protein synthesis and metabolism, modulation of transcription process, chromatin remodeling, calcium signaling, and mTOR and oxytocin pathways have also been implicated [858687]. </plain></SENT>
<SENT sid="98" pm="."><plain>This suggests that genes involved in ASD might be related each other in several convergent functional units, especially in neuronal development, modulation, and intracellular transcriptional mechanisms. </plain></SENT>
<SENT sid="99" pm="."><plain>As more and more causative genes of ASD are identified, their interaction within the context of functional significance would be clarified. </plain></SENT>
<SENT sid="100" pm="."><plain>Molecular pathways possibly involved in pathogenesis of ASD are summarized in Fig. 1 [86]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="101" pm="."><plain>Genes and brain circuits </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>Theoretically, ASD is an end-product of gene-environment interaction, mediated by changes in brain physiology, function, and morphology causing cognitive and behavioral dysfunction. </plain></SENT>
<SENT sid="103" pm="."><plain>Multiple brain areas involving facial recognition, emotion evaluation, empathy, mentalization, social cognition and behavior are known to be associated with ASD as part of the "social brain network" [88]. </plain></SENT>
<SENT sid="104" pm="."><plain>Alterations in brain connectivity and morphology might be a potential endophenotypes of ASD. </plain></SENT>
<SENT sid="105" pm="."><plain>However, not many human studies have explored associations between specific genetic variants and brain circuits or morphological phenotypes. </plain></SENT>
<SENT sid="106" pm="."><plain>One recent study examined phenotypic characteristics of subjects with ASD carrying germline heterogeneous PTEN mutations (PTEN-ASD); compared to subjects with idiopathic (non-PTEN) ASD and healthy controls, subjects with PTEN-ASD showed prominent cognitive dysfunction and white-matter abnormalities, mediated by reductions in the PTEN protein [89]. </plain></SENT>
<SENT sid="107" pm="."><plain>Moreover, significant differences in fMRI activation and deactivation patterns to social stimuli as well as functional and structural connectivity in the temporo-parietal region based on the existence of the rs1858830 MET risk allele (C/C) highlighted alterations in gene-brain pathway in ASD [14]. </plain></SENT>
<SENT sid="108" pm="."><plain>More data are necessary to understand the complex pathways connecting specific genetic mutation/genotype and brain changes, which have a direct impact on specific behavioral phenotypes of ASD. </plain></SENT>
</text></p></sec></sec><SecTag type="RESULTS"><sec><title><text><SENT sid="109" pm="."><plain>GENETICS USED FOR DIAGNOSIS AND THERAPEUTIC TARGETS: CLINICAL REALM </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>The ultimate goal of the evaluation of genetic etiology in complex disorders is the discovery of biomarkers for risk assessment, diagnosis, and prediction of therapeutic responses and prognoses, and the development of therapeutic components. </plain></SENT>
<SENT sid="111" pm="."><plain>The current best estimate diagnosis of ASD is based on behavioral observation and developmental history, assisted by standardized diagnostic instruments. </plain></SENT>
<SENT sid="112" pm="."><plain>While it is strongly suggested that early intervention in ASD can promote better prognoses, reduce secondary behavioral complications, and even induce normalization of brain activity [90], diagnostic confirmation before 2 years of age based only on the behavioral observations has limitations. </plain></SENT>
<SENT sid="113" pm="."><plain>Thus, the identification of genetic markers will provide useful information to aid in the early diagnosis of ASD in infants and begin early intervention. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>However, the current status of genetic diagnoses of ASD is insufficient in clinical utility and precision for general applications. </plain></SENT>
<SENT sid="115" pm="."><plain>While known genetic causes are identified in 20-25% of ASD, each of those mutations/variants are rare and account for only 1-2% of the probands [69192], which means there are no single predictable genetic markers for the development of ASD. </plain></SENT>
<SENT sid="116" pm="."><plain>As described previously, scientists believe that ASD is the product of the interplay between multiple common and rare genetic variants, and that genetic diagnosis should involve a combination of multiple genetic markers as a form of targeted gene panels. </plain></SENT>
<SENT sid="117" pm="."><plain>There have been attempts to make a gene set to diagnose ASD: for example, Skafidas et al. (2012) identified a group of SNPs selected by pathway analysis, and applied machine learning to the identified SNPs to generate a predictive classifier for ASD diagnosis. </plain></SENT>
<SENT sid="118" pm="."><plain>By applying 237 highly significant SNPs to three independent cohorts, there was a high level of diagnostic accuracy observed in genetically homogenous populations (84.3-85.6%), but not in an ethnically distinct cohort of Han Chinese (56%) [93]. </plain></SENT>
<SENT sid="119" pm="."><plain>Despite small sample sizes and the preliminary nature of the methodology, other researchers applied gene panels on subgroups of ASD and observed 75-90% accuracy in classification [94]. </plain></SENT>
<SENT sid="120" pm="."><plain>These studies may imply that development of a diagnosis based on genetic markers needs consider ethnic diversity and phenotypic heterogeneity. </plain></SENT>
<SENT sid="121" pm="."><plain>There are several gene panels offered by clinical molecular laboratories, but their clinical validity has not yet been fully evaluated [95]. </plain></SENT>
<SENT sid="122" pm="."><plain>In the future, next generation sequencing (NGS) is expected to produce a level of resolution down to the single base pair level and to enhance the assay precision level, but diagnostic validity should proceed so that the technology works in a clinically valid way [96]. </plain></SENT>
</text></p><p><text><SENT sid="123" pm="."><plain>In its current status, clinical value is primarily focused on the identification of known genetic causes of ASD. </plain></SENT>
<SENT sid="124" pm="."><plain>It is recommended that once a clinical diagnosis of ASD is made, genetic testing should be initiated [96]. </plain></SENT>
<SENT sid="125" pm="."><plain>This includes single-gene tests for monogenic causes of ASD, including fragile X syndrome, tuberous sclerosis complex, Rett syndrome, Angelman syndrome, Prader-Willi syndrome, phosphatase and tensin homolog (PTEN)-associated disorders, Noonan syndrome, cortical dysplasia-focal epilepsy syndrome (associated with CNTNAP2), and Phelan-McDermid syndrome, by detecting point mutations, microdeletions, duplications, and large repeat expansions using sequencing, fluorescence in situ hybridization (FISH), and Southern blotting technologies [95]. </plain></SENT>
<SENT sid="126" pm="."><plain>An assay for CNVs with array comparative genomic hybridization (aCGH) is also available for known variations of ASD [96]. </plain></SENT>
<SENT sid="127" pm="."><plain>At the clinical level, practice guidelines of the American College of Medical Genetics (ACMG) recommends a three generation family history with pedigree analyses; an initial evaluation for known syndromes associated with ASD, especially if the subject has dysmorphic features or specific clinical indicators; a chromosomal microarray; and DNA testing for fragile X for all male children suspected of an ASD as the first tier genetic evaluation. </plain></SENT>
<SENT sid="128" pm="."><plain>ACMG recommends sequencing and duplication testing for the MECP2 gene in female patients, and PTEN testing for those with macrocephaly as second tier genetic testing [9798]. </plain></SENT>
</text></p><p><text><SENT sid="129" pm="."><plain>There are ethical considerations of the clinical use of genetic testing and counseling for ASD. </plain></SENT>
<SENT sid="130" pm="."><plain>First, it is important that biomarker discovery, especially commercialization of biomarker data in autism, does not result in children being given a biological label that fixes and defines their potential and treatment [99100]. </plain></SENT>
<SENT sid="131" pm="."><plain>Second, genetic biomarker results have a huge impact on parental decision-making toward reproduction; therefore, more research and communication is needed for a better understanding of parental needs and attitudes [100]. </plain></SENT>
</text></p><p><text><SENT sid="132" pm="."><plain>Pharmacological treatment of ASD is primarily focused on improving comorbid behavioral emotional symptoms, such as irritability, aggression, anxiety, tics, self-injurious behaviors, and epilepsy [101]. </plain></SENT>
<SENT sid="133" pm="."><plain>One of the ultimate goals of the discovery and validation of biomarkers is developing molecular therapeutics to treat the core symptoms of ASD, based on knowledge about disease modifying mechanisms. </plain></SENT>
<SENT sid="134" pm="."><plain>Identification of causative genes, especially from high-throughput methods such as NGS, is paving the way for developing pharmacological agents to treat the core symptoms of ASD, including abnormal reciprocal social interaction and communication. </plain></SENT>
<SENT sid="135" pm="."><plain>Several recent well-designed studies have modeled human genetic variants associated with ASD in mice, using SHANK3, CNTNAP2, MECP2, UBE3A, and FMR1 genes, and are refining potential therapeutic mechanisms [78102103104105106]. </plain></SENT>
<SENT sid="136" pm="."><plain>These studies refine the function of genetic biomarkers of autism and relate them to behavioral phenotypes, and suggest potential target compounds for recovery of function. </plain></SENT>
<SENT sid="137" pm="."><plain>However, it is only the beginning of the discovery of therapeutic molecules for human subjects, covering the heterogeneity and complexity of the molecular pathways of autism. </plain></SENT>
</text></p><p><text><SENT sid="138" pm="."><plain>A few empirical trials have begun for syndromic autism with well-known monogenic etiology, with hopes to expand the trial for idiopathic ASD. </plain></SENT>
<SENT sid="139" pm="."><plain>Tuberous sclerosis is one of the examples; the TSC1 and TSC2 genes encode proteins regulating the mTORC1 protein complex. </plain></SENT>
<SENT sid="140" pm="."><plain>mTOR plays an important role in protein synthesis, cell growth, and axon formation. </plain></SENT>
<SENT sid="141" pm="."><plain>mTOR inhibitors (including rapamycin and everolimus) are currently being tested for their effect on neurocognitive outcomes in children with tuberous sclerosis complex, with outcome measurements that include autism symptoms, cognition, language skills, and behavior [79107]. </plain></SENT>
<SENT sid="142" pm="."><plain>Also clinical trials using mechanism-based targeted treatment for Dup15q syndrome (duplication of 15q11.2-q13) and fragile X syndrome are also under way [3798107]. </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>Oxytocin is neuromodulatory hormone involved in various social behaviors in humans and animals, including parents-offspring bonding, affection, social recognition, and social antagonism [17]. </plain></SENT>
<SENT sid="144" pm="."><plain>Although inconsistencies in genetic studies of OXTR in ASD, positive associations have been reported in multiple studies and across multiple ethnicities. </plain></SENT>
<SENT sid="145" pm="."><plain>Significant hypermethylation of critical sites of OXTR was observed in subjects with ASD and in the brother of a proband with OXTR deletion implicated epigenetic modification of the OXTR gene in ASD [26108109]. OXTR knock-out animal models show various characteristics of social behavior including parental nurturing, pair bonding, and social memory as well as brain changes in the limbic and paralimbic regions [110111]. </plain></SENT>
<SENT sid="146" pm="."><plain>Based on strong coherent evidence from human and animal studies across genetic, neural, and behavioral levels, oxytocin has been chosen as a pharmacological agent targeting core symptoms of ASD. </plain></SENT>
<SENT sid="147" pm="."><plain>A few randomized controlled trials have showed the efficacy of intravenous or nasal administration of oxytocin in core domains of ASD, such as social cognition and behavior. </plain></SENT>
<SENT sid="148" pm="."><plain>A few well-designed studies have reported enhanced performance in empathy tasks accompanied by increased anterior insula activity and coordination in the medical prefrontal cortex [112113114]. </plain></SENT>
<SENT sid="149" pm="."><plain>Although there are unmet limitations in the generalizability of subjects, establishment of dosage and route of administration, and maintenance of effect and safety in children, oxytocin might be a potential therapeutic agent for core symptoms of ASD with the most achievable clinical utility. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="150" pm="."><plain>NGS IN ASD GENETICS </plain></SENT>
</text></title><p><text><SENT sid="151" pm="."><plain>High-throughput technologies have facilitated gene discovery in ASD. </plain></SENT>
<SENT sid="152" pm="."><plain>The most recent development, NGS, which include whole-genome sequencing (WGS), whole-exome sequencing (WES), and targeted sequencing, promotes the precise identification of genetic variants at base-by-base levels. </plain></SENT>
<SENT sid="153" pm="."><plain>NGS promotes the identification of rare alleles to a degree not possible using genotyping platforms, and allows identification of single gene defects and partial variations of gene function [37115]. </plain></SENT>
<SENT sid="154" pm="."><plain>NGS in ASD is still emerging; it is useful to identify novel de novo variants not observed by conventional methods. </plain></SENT>
<SENT sid="155" pm="."><plain>Recent studies have confirmed de novo CNV loci in large-sized cohorts of idiopathic ASD families, observed new candidate loci, and confirmed de novo mutations in subjects with ASD and other neuropsychological abnormalities [58116117118]. </plain></SENT>
<SENT sid="156" pm="."><plain>Regarding diagnostic utility, one recent study reported complicated results that the diagnostic yield of WES is comparable to chromosomal microarray, while combined diagnostic yield is higher among children with more complex morphological phenotypes, emphasizing the importance of phenotypic classification [119]. </plain></SENT>
</text></p><p><text><SENT sid="157" pm="."><plain>Although NGS is not yet widespread due to its relatively high cost and the demand for techniques involving large-scale data and bioinformatics, it is predicted that large-scale investigations combining NGS technology and accumulated clinical data will facilitate the genetic study of ASD from diagnoses to targeted treatments in the future [5]. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec sec-type="conclusions"><title><text><SENT sid="158" pm="."><plain>CONCLUSION </plain></SENT>
</text></title><p><text><SENT sid="159" pm="."><plain>A wide range of genetic variation is involved in ASD, with interplays of gene-gene and gene-environment interactions. </plain></SENT>
<SENT sid="160" pm="."><plain>Both genotypic and phenotypic heterogeneity contribute to the difficulty in the thorough exploration and confirmation of causative genetic factors. </plain></SENT>
<SENT sid="161" pm="."><plain>However, recent technological developments, including NGS, and the accumulation of clinical information are bridging the gap in the application of genetic knowledge towards clinical practice. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="COMP_INT"><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by the Korea Healthcare Technology R&amp;D Project (A120029) from the Ministry of Health and Welfare, Republic of Korea. The author has no conflict of interests to declare.</p></ack></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="162" pm="."><plain>1BaileyALe CouteurAGottesmanIBoltonPSimonoffEYuzdaERutterMAutism as a strongly genetic disorder: evidence from a British twin studyPsychol Med19952563777792363 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="163" pm="."><plain>2OzonoffSYoungGSCarterAMessingerDYirmiyaNZwaigenbaumLBrysonSCarverLJConstantinoJNDobkinsKHutmanTIversonJMLandaRRogersSJSigmanMStoneWLRecurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium studyPediatrics2011128e488e49521844053 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="164" pm="."><plain>3De RubeisSBuxbaumJDGenetics and genomics of autism spectrum disorder: embracing complexityHum Mol Genet201524R1R24R3126188008 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="165" pm="."><plain>4HallmayerJClevelandSTorresAPhillipsJCohenBTorigoeTMillerJFedeleACollinsJSmithKLotspeichLCroenLAOzonoffSLajonchereCGretherJKRischNGenetic heritability and shared environmental factors among twin pairs with autismArch Gen Psychiatry2011681095110221727249 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="166" pm="."><plain>5GeschwindDHStateMWGene hunting in autism spectrum disorder: on the path to precision medicineLancet Neurol2015141109112025891009 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="167" pm="."><plain>6VoineaguIYooHJCurrent progress and challenges in the search for autism biomarkersDis Markers201335556524167349 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="168" pm="."><plain>7GauglerTKleiLSandersSJBodeaCAGoldbergAPLeeABMahajanMManaaDPawitanYReichertJRipkeSSandinSSklarPSvantessonOReichenbergAHultmanCMDevlinBRoederKBuxbaumJDMost genetic risk for autism resides with common variationNat Genet20144688188525038753 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="169" pm="."><plain>8KleiLSandersSJMurthaMTHusVLoweJKWillseyAJMoreno-De-LucaDYuTWFombonneEGeschwindDGriceDELedbetterDHLordCManeSMMartinCLMartinDMMorrowEMWalshCAMelhemNMChastePSutcliffeJSStateMWCookEHJrRoederKDevlinBCommon genetic variants, acting additively, are a major source of risk for autismMol Autism20123923067556 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="170" pm="."><plain>9ZhuMZhaoSCandidate gene identification approach: progress and challengesInt J Biol Sci2007342042717998950 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="171" pm="."><plain>10LoshMSullivanPFTrembathDPivenJCurrent developments in the genetics of autism: from phenome to genomeJ Neuropathol Exp Neurol20086782983718716561 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="172" pm="."><plain>11SutcliffeJSDelahantyRJPrasadHCMcCauleyJLHanQJiangLLiCFolsteinSEBlakelyRDAllelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviorsAm J Hum Genet20057726527915995945 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="173" pm="."><plain>12MaDQRabionetRKonidariIJaworskiJCukierHNWrightHHAbramsonRKGilbertJRCuccaroMLPericak-VanceMAMartinERAssociation and gene-gene interaction of SLC6A4 and ITGB3 in autismAm J Med Genet B Neuropsychiatr Genet2010153B47748319588468 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="174" pm="."><plain>13KimSAKimJHParkMChoIHYooHJAssociation of GABRB3 polymorphisms with autism spectrum disorders in Korean triosNeuropsychobiology20065416016517230033 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="175" pm="."><plain>14RudieJDHernandezLMBrownJABeck-PancerDColichNLGorrindoPThompsonPMGeschwindDHBookheimerSYLevittPDaprettoMAutism-associated promoter variant in MET impacts functional and structural brain networksNeuron20127590491522958829 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="176" pm="."><plain>15PenagarikanoOGeschwindDCNTNAP2 and autism spectrum disordersPowelCMThe autismsNew York, NYOxford University Press2013274285 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="177" pm="."><plain>16YangSYChoSCYooHJChoIHParkMYoeJKimSAFamily-based association study of microsatellites in the 5flanking region of AVPR1A with autism spectrum disorder in the Korean populationPsychiatry Res201017819920120452058 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="178" pm="."><plain>17YamasueHPromising evidence and remaining issues regarding the clinical application of oxytocin in autism spectrum disordersPsychiatry Clin Neurosci2015in press </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="179" pm="."><plain>18PersicoAMNapolioniVAutism geneticsBehav Brain Res20132519511223769996 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="180" pm="."><plain>19WangLJiaMYueWTangFQuMRuanYLuTZhangHYanHLiuJGuoYZhangJYangXZhangDAssociation of the ENGRAILED 2 (EN2) gene with autism in Chinese Han populationAm J Med Genet B Neuropsychiatr Genet2008147B43443817948901 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="181" pm="."><plain>20LeeEJChoiSYKimENMDA receptor dysfunction in autism spectrum disordersCurr Opin Pharmacol20152081325636159 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="182" pm="."><plain>21YooHJChoIHParkMYangSYKimSAFamily based association of GRIN2A and GRIN2B with Korean autism spectrum disordersNeurosci Lett2012512899322326929 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="183" pm="."><plain>22SkaarDAShaoYHainesJLStengerJEJaworskiJMartinERDeLongGRMooreJHMcCauleyJLSutcliffeJSAshley-KochAECuccaroMLFolsteinSEGilbertJRPericak-VanceMAAnalysis of the RELN gene as a genetic risk factor for autismMol Psychiatry20051056357115558079 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="184" pm="."><plain>23BuxbaumJDSilvermanJMSmithCJGreenbergDAKilifarskiMReichertJCookEHJrFangYSongCYVitaleRAssociation between a GABRB3 polymorphism and autismMol Psychiatry2002731131611920158 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="185" pm="."><plain>24MartinERMenoldMMWolpertCMBassMPDonnellySLRavanSAZimmermanAGilbertJRVanceJMMaddoxLOWrightHHAbramsonRKDeLongGRCuccaroMLPericak-VanceMAAnalysis of linkage disequilibrium in gamma-aminobutyric acid receptor subunit genes in autistic disorderAm J Med Genet200096434810686550 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="186" pm="."><plain>25VorstmanJASpoorenWPersicoAMCollierDAAignerSJagasiaRGlennonJCBuitelaarJKUsing genetic findings in autism for the development of new pharmaceutical compoundsPsychopharmacology(Berl)20142311063107824292384 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="187" pm="."><plain>26LererELeviSSalomonSDarvasiAYirmiyaNEbsteinRPAssociation between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognitionMol Psychiatry20081398098817893705 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="188" pm="."><plain>27PretiAMelisMSiddiSVellanteMDonedduGFaddaROxytocin and autism: a systematic review of randomized controlled trialsJ Child Adolesc Psychopharmacol201424546824679173 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="189" pm="."><plain>28CollinsALSullivanPFGenome-wide association studies in psychiatry: what have we learned?Br J Psychiatry20132021423284144 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="190" pm="."><plain>29MaDSalyakinaDJaworskiJMKonidariIWhiteheadPLAndersenANHoffmanJDSliferSHHedgesDJCukierHNGriswoldAJMcCauleyJLBeechamGWWrightHHAbramsonRKMartinERHussmanJPGilbertJRCuccaroMLHainesJLPericak-VanceMAA genome-wide association study of autism reveals a common novel risk locus at 5p14.1Ann Hum Genet20097326327319456320 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="191" pm="."><plain>30WangKZhangHMaDBucanMGlessnerJTAbrahamsBSSalyakinaDImielinskiMBradfieldJPSleimanPMKimCEHouCFrackeltonEChiavacciRTakahashiNSakuraiTRappaportELajonchereCMMunsonJEstesAKorvatskaOPivenJSonnenblickLIAlvarez RetuertoAIHermanEIDongHHutmanTSigmanMOzonoffSKlinAOwleyTSweeneyJABruneCWCantorRMBernierRGilbertJRCuccaroMLMcMahonWMMillerJStateMWWassinkTHCoonHLevySESchultzRTNurnbergerJIHainesJLSutcliffeJSCookEHMinshewNJBuxbaumJDDawsonGGrantSFGeschwindDHPericak-VanceMASchellenbergGDHakonarsonHCommon genetic variants on 5p14.1 associate with autism spectrum disordersNature200945952853319404256 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="192" pm="."><plain>31WeissLAArkingDEDalyMJChakravartiAArkingDEBruneCWWestKO'ConnorAHiltonGTomlinsonRLWestABCookEHJrChakravartiAWeissLAGreenTChangSCGabrielSGatesCHansonEMKirbyAKornJKuruvillaFMcCarrollSMorrowEMNealeBPurcellSSasanfarRSougnezCStevensCAltshulerDGusellaJSantangeloSLSklarPTanziRDalyMJAnneyRBaileyAJBairdGBattagliaABerneyTBetancurCBÃ¶lteSBoltonPFBrianJBrysonSEBuxbaumJDCabritoICaiGCantorRMCookEHJrCoonHConroyJCorreiaCCorselloCCrawfordELCuccaroMLDawsonGde JongeMDevlinBDuketisEEnnisSEstesAFarrarPFombonneEFreitagCMGallagherLGeschwindDHGilbertJGillMGillbergCGoldbergJGreenAGreenJGuterSJHainesJLHallmayerJFHusVKlauckSMKorvatskaOLambJALaskawiecMLeboyerMLe CouteurALeventhalBLLiuXQLordCLotspeichLJMaestriniEMagalhaesTMahoneyWMantoulanCMcConachieHMcDougleCJMcMahonWMMarshallCRMillerJMinshewNJMonacoAPMunsonJNurnbergerJIJrOliveiraGPagnamentaAPapanikolaouKParrJRPatersonADPericak-VanceMAPicklesAPintoDPivenJPoseyDJPoustkaAPoustkaFReganRReichertJRenshawKRobertsWRogeBRutterMLSaltJSchellenbergGDSchererSWSheffieldVSutcliffeJSSzatmariPTanseyKThompsonAPTsiantisJVan EngelandHVicenteAMVielandVJVolkmarFWallaceSWassinkTHWijsmanEMWingKWittemeyerKYaspanBLZwaigenbaumLMorrowEMYooSYSean HillRMukaddesNMBalkhySGasconGAl-SaadSHashmiAWareJJosephRMLeClairEPartlowJNBarryBWalshCAPaulsDMoilanenIEbelingHMattilaMLKuusikkoSJussilaKIgnatiusJSasanfarRToloueiAGhadamiMRostamiMHosseinipourAValujerdiMSantangeloSLAndresenKWinkloskiBHaddadSKunkelLKohaneZTranTWon KongSO'NeilSBHansonEMHundleyRHolmIPetersHBaroniECangialoseAJacksonLAlbersLBeckerRBridgemohanCFriedmanSMunirKNazirRPalfreyJSchonwaldASimmonsERappaportLAGauthierJMottronLJooberRFombonneERouleauGRehnstromKvon WendtLPeltonenLGene Discovery Project of Johns Hopkins &amp; the Autism ConsortiumA genome-wide linkage and association scan reveals novel loci for autismNature200946180280819812673 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="193" pm="."><plain>32AnneyRKleiLPintoDReganRConroyJMagalhaesTRCorreiaCAbrahamsBSSykesNPagnamentaATAlmeidaJBacchelliEBaileyAJBairdGBattagliaABerneyTBolshakovaNBÃ¶lteSBoltonPFBourgeronTBrennanSBrianJCarsonARCasalloGCaseyJChuSHCochraneLCorselloCCrawfordELCrossettADawsonGde JongeMDelormeRDrmicIDuketisEDuqueFEstesAFarrarPFernandezBAFolsteinSEFombonneEFreitagCMGilbertJGillbergCGlessnerJTGoldbergJGreenJGuterSJHakonarsonHHeronEAHillMHoltRHoweJLHughesGHusVIgliozziRKimCKlauckSMKolevzonAKorvatskaOKustanovichVLajonchereCMLambJALaskawiecMLeboyerMLe CouteurALeventhalBLLionelACLiuXQLordCLotspeichLLundSCMaestriniEMahoneyWMantoulanCMarshallCRMcConachieHMcDougleCJMcGrathJMcMahonWMMelhemNMMerikangasAMigitaOMinshewNJMirzaGKMunsonJNelsonSFNoakesCNoorANygrenGOliveiraGPapanikolaouKParrJRParriniBPatonTPicklesAPivenJPoseyDJPoustkaAPoustkaFPrasadARagoussisJRenshawKRickabyJRobertsWRoederKRogeBRutterMLBierutLJRiceJPSaltJSansomKSatoDSeguradoRSenmanLShahNSheffieldVCSooryaLSousaIStoppioniVStrawbridgeCTancrediRTanseyKThiruvahindrapduramBThompsonAPThomsonSTryfonATsiantisJVan EngelandHVincentJBVolkmarFWallaceSWangKWangZWassinkTHWingKWittemeyerKWoodSYaspanBLZurawieckiDZwaigenbaumLBetancurCBuxbaumJDCantorRMCookEHCoonHCuccaroMLGallagherLGeschwindDHGillMHainesJLMillerJMonacoAPNurnbergerJIJrPatersonADPericak-VanceMASchellenbergGDSchererSWSutcliffeJSSzatmariPVicenteAMVielandVJWijsmanEMDevlinBEnnisSHallmayerJA genome-wide scan for common alleles affecting risk for autismHum Mol Genet2010194072408220663923 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="194" pm="."><plain>33ConnollyJJGlessnerJTHakonarsonHA genome-wide association study of autism incorporating autism diagnostic interview-revised, autism diagnostic observation schedule, and social responsiveness scaleChild Dev201384173322935194 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="195" pm="."><plain>34ChastePKleiLSandersSJHusVMurthaMTLoweJKWillseyAJMoreno-De-LucaDYuTWFombonneEGeschwindDGriceDELedbetterDHManeSMMartinDMMorrowEMWalshCASutcliffeJSLese MartinCBeaudetALLordCStateMWCookEHJrDevlinBA genome-wide association study of autism using the Simons Simplex Collection: Does reducing phenotypic heterogeneity in autism increase genetic homogeneity?Biol Psychiatry20157777578425534755 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="196" pm="."><plain>35LiuXShimadaTOtowaTWuYYKawamuraYTochigiMIwataYUmekageTToyotaTMaekawaMIwayamaYSuzukiKKakiuchiCKuwabaraHKanoYNishidaHSugiyamaTKatoNChenCHMoriNYamadaKYoshikawaTKasaiKTokunagaKSasakiTGauSSGenome-wide Association Study of Autism Spectrum Disorder in the East Asian PopulationsAutism Resin press </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="197" pm="."><plain>36HagbergBRett syndrome: clinical peculiarities and biological mysteriesActa Paediatr1995849719768652969 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="198" pm="."><plain>37VeltmanMWCraigEEBoltonPFAutism spectrum disorders in Prader-Willi and Angelman syndromes: a systematic reviewPsychiatr Genet20051524325416314754 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="199" pm="."><plain>38LiuXTakumiTGenomic and genetic aspects of autism spectrum disorderBiochem Biophys Res Commun201445224425325173933 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="200" pm="."><plain>39GlessnerJTWangKCaiGKorvatskaOKimCEWoodSZhangHEstesABruneCWBradfieldJPImielinskiMFrackeltonECReichertJCrawfordELMunsonJSleimanPMChiavacciRAnnaiahKThomasKHouCGlabersonWFloryJOtienoFGarrisMSooryaLKleiLPivenJMeyerKJAnagnostouESakuraiTGameRMRuddDSZurawieckiDMcDougleCJDavisLKMillerJPoseyDJMichaelsSKolevzonASilvermanJMBernierRLevySESchultzRTDawsonGOwleyTMcMahonWMWassinkTHSweeneyJANurnbergerJICoonHSutcliffeJSMinshewNJGrantSFBucanMCookEHBuxbaumJDDevlinBSchellenbergGDHakonarsonHAutism genome-wide copy number variation reveals ubiquitin and neuronal genesNature200945956957319404257 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="201" pm="."><plain>40MarshallCRNoorAVincentJBLionelACFeukLSkaugJShagoMMoessnerRPintoDRenYThiruvahindrapduramBFiebigASchreiberSFriedmanJKetelaarsCEVosYJFiciciogluCKirkpatrickSNicolsonRSlomanLSummersAGibbonsCATeebiAChitayatDWeksbergRThompsonAVardyCCrosbieVLuscombeSBaatjesRZwaigenbaumLRobertsWFernandezBSzatmariPSchererSWStructural variation of chromosomes in autism spectrum disorderAm J Hum Genet20088247748818252227 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="202" pm="."><plain>41SebatJLakshmiBMalhotraDTrogeJLese-MartinCWalshTYamromBYoonSKrasnitzAKendallJLeottaAPaiDZhangRLeeYHHicksJSpenceSJLeeATPuuraKLehtimÃ¤kiTLedbetterDGregersenPKBregmanJSutcliffeJSJobanputraVChungWWarburtonDKingMCSkuseDGeschwindDHGilliamTCYeKWiglerMStrong association of de novo copy number mutations with autismScience200731644544917363630 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="203" pm="."><plain>42TalkowskiMEMinikelEVGusellaJFAutism spectrum disorder genetics: diverse genes with diverse clinical outcomesHarv Rev Psychiatry201422657524614762 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="204" pm="."><plain>43KumarRASudiJBabatzTDBruneCWOswaldDYenMNowakNJCookEHChristianSLDobynsWBA de novo 1p34.2 microdeletion identifies the synaptic vesicle gene RIMS3 as a novel candidate for autismJ Med Genet201047819019546099 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="205" pm="."><plain>44LiangJSShimojimaKOhnoKSugiuraCUneYOhnoKYamamotoTA newly recognised microdeletion syndrome of 2p15-16.1 manifesting moderate developmental delay, autistic behaviour, short stature, microcephaly, and dysmorphic features: a new patient with 3.2 Mb deletionJ Med Genet20094664564719724011 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="206" pm="."><plain>45LiuXMalenfantPReesorCLeeAHudsonMLHarvardCQiaoYPersicoAMCohenILChudleyAEForster-GibsonCRajcan-SeparovicELewisMEHoldenJJ2p15-p16.1 microdeletion syndrome: molecular characterization and association of the OTX1 and XPO1 genes with autism spectrum disordersEur J Hum Genet2011191264127021750575 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="207" pm="."><plain>46MillerDTShenYWeissLAKornJAnselmIBridgemohanCCoxGFDickinsonHGentileJHarrisDJHegdeVHundleyRKhwajaOKothareSLuedkeCNasirRPoduriAPrasadKRaffalliPReinhardASmithSESobeihMMSoulJSStolerJTakeokaMTanWHThakuriaJWolffRYusupovRGusellaJFDalyMJWuBLMicrodeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disordersJ Med Genet20094624224818805830 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="208" pm="."><plain>47PagnamentaATWingKSadighi AkhaEKnightSJBÃ¶lteSSchmÃ¶tzerGDuketisEPoustkaFKlauckSMPoustkaARagoussisJBaileyAJMonacoAPInternational Molecular Genetic Study of Autism ConsortiumA 15q13.3 microdeletion segregating with autismEur J Hum Genet20091768769219050728 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="209" pm="."><plain>48Rajcan-SeparovicEHarvardCLiuXMcGillivrayBHallJGQiaoYHurlburtJHildebrandJMickelsonECHoldenJJLewisMEClinical and molecular cytogenetic characterisation of a newly recognised microdeletion syndrome involving 2p15-16.1J Med Genet20074426927616963482 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="210" pm="."><plain>49WeissLAShenYKornJMArkingDEMillerDTFossdalRSaemundsenEStefanssonHFerreiraMAGreenTPlattOSRuderferDMWalshCAAltshulerDChakravartiATanziREStefanssonKSantangeloSLGusellaJFSklarPWuBLDalyMJAutism ConsortiumAssociation between microdeletion and microduplication at 16p11.2 and autismN Engl J Med200835866767518184952 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="211" pm="."><plain>50DurandCMBetancurCBoeckersTMBockmannJChastePFauchereauFNygrenGRastamMGillbergICAnckarsÃ¤terHSponheimEGoubran-BotrosHDelormeRChabaneNMouren-SimeoniMCde MasPBiethERogÃ©BHÃ©ronDBurglenLGillbergCLeboyerMBourgeronTMutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disordersNat Genet200739252717173049 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="212" pm="."><plain>51GauthierJBonnelASt-OngeJKaremeraLLaurentSMottronLFombonneEJooberRRouleauGANLGN3/NLGN4 gene mutations are not responsible for autism in the Quebec populationAm J Med Genet B Neuropsychiatr Genet2005132B747515389766 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="213" pm="."><plain>52GrafERZhangXJinSXLinhoffMWCraigAMNeurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroliginsCell20041191013102615620359 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="214" pm="."><plain>53JamainSQuachHBetancurCRÃ¥stamMColineauxCGillbergICSoderstromHGirosBLeboyerMGillbergCBourgeronTGillbergCRÃ¥stamMGillbergCNydÃ©nASÃ¶derstrÃ¶mHLeboyerMBetancurCPhilippeAGirosBColineauxCCohenDChabaneNMouren-SimÃ©oniMCBriceASponheimESpurklandISkjeldalOHColemanMPearlPLCohenILTsiourisJZappellaMMenchettiGPompellaAAschauerHVan MaldergemLParis Autism Research International Sibpair StudyMutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autismNat Genet200334272912669065 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="215" pm="."><plain>54LaumonnierFBonnet-BrilhaultFGomotMBlancRDavidAMoizardMPRaynaudMRonceNLemonnierECalvasPLaudierBChellyJFrynsJPRopersHHHamelBCAndresCBarthÃ©lÃ©myCMoraineCBriaultSX-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin familyAm J Hum Genet20047455255714963808 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="216" pm="."><plain>55Lawson-YuenASaldivarJSSommerSPickerJFamilial deletion within NLGN4 associated with autism and Tourette syndromeEur J Hum Genet20081661461818231125 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="217" pm="."><plain>56MaÄkowiakMMordalskaPWÄdzonyKNeuroligins, synapse balance and neuropsychiatric disordersPharmacol Rep20146683083525149987 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="218" pm="."><plain>57MoessnerRMarshallCRSutcliffeJSSkaugJPintoDVincentJZwaigenbaumLFernandezBRobertsWSzatmariPSchererSWContribution of SHANK3 mutations to autism spectrum disorderAm J Hum Genet2007811289129717999366 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="219" pm="."><plain>58NemirovskySICÃ³rdobaMZaiatJJCompletaSPVegaPAGonzÃ¡lez-MorÃ³nDMedinaNMFabbroMRomeroSBrunBRevaleSOgaraMFPecciAMartiMVazquezMTurjanskiAKauffmanMAWhole genome sequencing reveals a de novo SHANK3 mutation in familial autism spectrum disorderPLoS One201510e011635825646853 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="220" pm="."><plain>59PhelanKMcDermidHEThe 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)Mol Syndromol2012218620122670140 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="221" pm="."><plain>60ReissnerCKloseMFairlessRMisslerMMutational analysis of the neurexin/neuroligin complex reveals essential and regulatory componentsProc Natl Acad Sci USA2008105151241512918812509 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="222" pm="."><plain>61TalebizadehZLamDYTheodoroMFBittelDCLushingtonGHButlerMGNovel splice isoforms for NLGN3 and NLGN4 with possible implications in autismJ Med Genet200643e2116648374 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="223" pm="."><plain>62XuXXiongZZhangLLiuYLuLPengYGuoHZhaoJXiaKHuZVariations analysis of NLGN3 and NLGN4X gene in Chinese autism patientsMol Biol Rep2014414133414024570023 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="224" pm="."><plain>63ShankarGMLiSMehtaTHGarcia-MunozAShepardsonNESmithIBrettFMFarrellMARowanMJLemereCAReganCMWalshDMSabatiniBLSelkoeDJAmyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNat Med20081483784218568035 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="225" pm="."><plain>64StephanKEFristonKJFrithCDDysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoringSchizophr Bull20093550952719155345 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="226" pm="."><plain>65ZhangCMilunskyJMNewtonSKoJZhaoGMaherTATager-FlusbergHBolligerMFCarterASBoucardAAPowellCMSÃ¼dhofTCA neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum exportJ Neurosci200929108431085419726642 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="227" pm="."><plain>66BoccutoLLauriMSarasuaSMSkinnerCDBuccellaDDwivediAOrteschiDCollinsJSZollinoMViscontiPDupontBTizianoDSchroerRJNeriGStevensonREGurrieriFSchwartzCEPrevalence of SHANK3 variants in patients with different subtypes of autism spectrum disordersEur J Hum Genet20132131031622892527 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="228" pm="."><plain>67DurandCMPerroyJLollFPerraisDFagniLBourgeronTMontcouquiolMSansNSHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanismMol Psychiatry201217718421606927 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="229" pm="."><plain>68MamezaMGDvoretskovaEBamannMHÃ¶nckHHGÃ¼lerTBoeckersTMSchoenMVerpelliCSalaCBarsukovIDityatevAKreienkampHJSHANK3 gene mutations associated with autism facilitate ligand binding to the Shank3 ankyrin repeat regionJ Biol Chem2013288266972670823897824 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="230" pm="."><plain>69UchinoSWagaCSHANK3 as an autism spectrum disorder-associated geneBrain Dev20133510611022749736 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="231" pm="."><plain>70SzatmariPPatersonADZwaigenbaumLRobertsWBrianJLiuXQVincentJBSkaugJLThompsonAPSenmanLFeukLQianCBrysonSEJonesMBMarshallCRSchererSWVielandVJBartlettCManginLVGoedkenRSegreAPericak-VanceMACuccaroMLGilbertJRWrightHHAbramsonRKBetancurCBourgeronTGillbergCLeboyerMBuxbaumJDDavisKLHollanderESilvermanJMHallmayerJLotspeichLSutcliffeJSHainesJLFolsteinSEPivenJWassinkTHSheffieldVGeschwindDHBucanMBrownWTCantorRMConstantinoJNGilliamTCHerbertMLajonchereCLedbetterDHLese-MartinCMillerJNelsonSSamango-SprouseCASpenceSStateMTanziRECoonHDawsonGDevlinBEstesAFlodmanPKleiLMcMahonWMMinshewNMunsonJKorvatskaERodierPMSchellenbergGDSmithMSpenceMAStodgellCTepperPGWijsmanEMYuCERogÃ©BMantoulanCWittemeyerKPoustkaAFelderBKlauckSMSchusterCPoustkaFBÃ¶lteSFeineis-MatthewsSHerbrechtESchmÃ¶tzerGTsiantisJPapanikolaouKMaestriniEBacchelliEBlasiFCaroneSTomaCVan EngelandHde JongeMKemnerCKoopFLangemeijerMHijmansCStaalWGBairdGBoltonPFRutterMLWeisblattEGreenJAldredCWilkinsonJAPicklesALe CouteurABerneyTMcConachieHBaileyAJFrancisKHoneymanGHutchinsonAParrJRWallaceSMonacoAPBarnbyGKobayashiKLambJASousaISykesNCookEHGuterSJLeventhalBLSaltJLordCCorselloCHusVWeeksDEVolkmarFTauberMFombonneEShihAMeyerKJAutism Genome Project ConsortiumMapping autism risk loci using genetic linkage and chromosomal rearrangementsNat Genet20073931932817322880 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="232" pm="."><plain>71BucanMAbrahamsBSWangKGlessnerJTHermanEISonnenblickLIAlvarez RetuertoAIImielinskiMHadleyDBradfieldJPKimCGidayaNBLindquistIHutmanTSigmanMKustanovichVLajonchereCMSingletonAKimJWassinkTHMcMahonWMOwleyTSweeneyJACoonHNurnbergerJILiMCantorRMMinshewNJSutcliffeJSCookEHDawsonGBuxbaumJDGrantSFSchellenbergGDGeschwindDHHakonarsonHGenome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genesPLoS Genet20095e100053619557195 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="233" pm="."><plain>72DabellMPRosenfeldJABaderPEscobarLFEl-KhechenDValleeSEDinulosMBCurryCFisherJTervoRHannibalMCSiefkasKWyattPRHughesLSmithREllingwoodSLacassieYStroudTFarrellSASanchez-LaraPARandolphLMNiyazovDStevensCASchoonveldCSkidmoreDMacKaySMilesJHMoodleyMHuilletANeillNJEllisonJWBallifBCShafferLGInvestigation of NRXN1 deletions clinical and molecular characterizationAm J Med Genet A2013161A71773123495017 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="234" pm="."><plain>73GlahnDCWilliamsJTMcKayDRKnowlesEESprootenEMathiasSRCurranJEKentJWJrCarlessMAGÃ¶ringHHDyerTDWoolseyMDWinklerAMOlveraRLKochunovPFoxPTDuggiralaRAlmasyLBlangeroJDiscovering schizophrenia endophenotypes in randomly ascertained pedigreesBiol Psychiatry201577758325168609 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="235" pm="."><plain>74ChenXShenYZhangFChiangCPillalamarriVBlumenthalITalkowskiMWuBLGusellaJFMolecular analysis of a deletion hotspot in the NRXN1 region reveals the involvement of short inverted repeats in deletion CNVsAm J Hum Genet20139237538623472757 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="236" pm="."><plain>75AlarcÃ³nMAbrahamsBSStoneJLDuvallJAPerederiyJVBomarJMSebatJWiglerMMartinCLLedbetterDHNelsonSFCantorRMGeschwindDHLinkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility geneAm J Hum Genet20088215015918179893 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="237" pm="."><plain>76ArkingDECutlerDJBruneCWTeslovichTMWestKIkedaMReaAGuyMLinSCookEHJrChakravartiAA common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autismAm J Hum Genet20088216016418179894 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="238" pm="."><plain>77BakkalogluBO'RoakBJLouviAGuptaARAbelsonJFMorganTMChawarskaKKlinAErcan-SencicekAGStillmanAATanrioverGAbrahamsBSDuvallJARobbinsEMGeschwindDHBiedererTGunelMLiftonRPStateMWMolecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disordersAm J Hum Genet20088216517318179895 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="239" pm="."><plain>78PeÃ±agarikanoOAbrahamsBSHermanEIWindenKDGdalyahuADongHSonnenblickLIGruverRAlmajanoJBraginAGolshaniPTrachtenbergJTPelesEGeschwindDHAbsence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficitsCell201114723524621962519 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="240" pm="."><plain>79MurdochJDGuptaARSandersSJWalkerMFKeaneyJFernandezTVMurthaMTAnyanwuSOberGTRaubesonMJDiLulloNMVillaNWaqarZSullivanCGonzalezLWillseyAJChoeSYNealeBMDalyMJStateMWNo evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or ContactinsPLoS Genet201511e100485225621974 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="241" pm="."><plain>80ChiocchettiAGKoppMWaltesRHaslingerDDuketisEJarczokTAPoustkaFVoranAGraabUMeyerJKlauckSMFuldaSFreitagCMVariants of the CNTNAP2 5 promoter as risk factors for autism spectrum disorders: a genetic and functional approachMol Psychiatry20152083984925224256 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="242" pm="."><plain>81PowelCMBoucardAANeuroligins and neurexins: bridging the synaptic cleft in autismPowelCMMonteggiaLMThe autismsNew York, NYOxford University Press2013214239 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="243" pm="."><plain>82BoucardAAChubykinAAComolettiDTaylorPSÃ¼dhofTCA splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexinsNeuron20054822923616242404 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="244" pm="."><plain>83PowelCMShank gene family and autismPowelCMMonteggiaLMThe autismsOxford University PressNew York, NY2013176188 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="245" pm="."><plain>84BÃ¶ckersTMMamezaMGKreutzMRBockmannJWeiseCBuckFRichterDGundelfingerEDKreienkampHJSynaptic scaffolding proteins in rat brain. </plain></SENT>
<SENT sid="246" pm="."><plain>Ankyrin repeats of the multidomain Shank protein family interact with the cytoskeletal protein alpha-fodrinJ Biol Chem2001276401044011211509555 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="247" pm="."><plain>85Ebrahimi-FakhariDSahinMAutism and the synapse: emerging mechanisms and mechanism-based therapiesCurr Opin Neurol2015289110225695134 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="248" pm="."><plain>86SahinMSurMGenes, circuits, and precision therapies for autism and related neurodevelopmental disordersScience2015350aab389726472761 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="249" pm="."><plain>87FeldmanRMonakhovMPrattMEbsteinRPOxytocin Pathway Genes: Evolut ionar y Ancient System Impacting on Human Affiliation, Sociality, and PsychopathologyBiol Psychiatrypii: S0006-3223(15)00656-3 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="250" pm="."><plain>88KennedyDPAdolphsRPerception of emotions from facial expressions in high-functioning adults with autismNeuropsychologia2012503313331923022433 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="251" pm="."><plain>89FrazierTWEmbacherRTilotAKKoenigKMesterJEngCMolecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autismMol Psychiatry2015201132113825288137 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="252" pm="."><plain>90DawsonGJonesEJMerkleKVenemaKLowyRFajaSKamaraDMuriasMGreensonJWinterJSmithMRogersSJWebbSJEarly behavioral intervention is associated with normalized brain activity in young children with autismJ Am Acad Child Adolesc Psychiatry2012511150115923101741 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="253" pm="."><plain>91AbrahamsBSGeschwindDHAdvances in autism genetics: on the threshold of a new neurobiologyNat Rev Genet2008934135518414403 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="254" pm="."><plain>92JesteSSGeschwindDHDisentangling the heterogeneity of autism spectrum disorder through genetic findingsNat Rev Neurol201410748124468882 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="255" pm="."><plain>93SkafidasETestaRZantomioDChanaGEverallIPPantelisCPredicting the diagnosis of autism spectrum disorder using gene pathway analysisMol Psychiatry20141950451022965006 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="256" pm="."><plain>94HuVWLaiYDeveloping a predictive gene classifier for autism spectrum disorders based upon differential gene expression profiles of phenotypic subgroupsN Am J Med Sci(Boston)20136 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="257" pm="."><plain>95JiangYHWangYXiuXChoyKWPursleyANCheungSWGenetic diagnosis of autism spectrum disorders: the opportunity and challenge in the genomics eraCrit Rev Clin Lab Sci20145124926224878448 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="258" pm="."><plain>96HeilKMSchaafCPThe genetics of Autism Spectrum Disorders--a guide for cliniciansCurr Psychiatry Rep20131533423250815 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="259" pm="."><plain>97SchaeferGBMendelsohnNJProfessional Practice and Guidelines CommitteeClinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisionsGenet Med20131539940723519317 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="260" pm="."><plain>98BakerEJesteSSDiagnosis and management of autism spectrum disorder in the era of genomics: rare disorders can pave the way for targeted treatmentsPediatr Clin North Am20156260761826022165 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="261" pm="."><plain>99SinghIRoseNBiomarkers in psychiatryNature200946020220719587761 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="262" pm="."><plain>100WalshPElsabbaghMBoltonPSinghIIn search of biomarkers for autism: scientific, social and ethical challengesNat Rev Neurosci20111260361221931335 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="263" pm="."><plain>101DoyleCAMcDougleCJPharmacotherapy to control behavioral symptoms in children with autismExpert Opin Pharmacother2012131615162922550944 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="264" pm="."><plain>102ChaoHTChenHSamacoRCXueMChahrourMYooJNeulJLGongSLuHCHeintzNEkkerMRubensteinJLNoebelsJLRosenmundCZoghbiHYDysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypesNature201046826326921068835 </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="265" pm="."><plain>103DÃ¶lenGOsterweilERaoBSSmithGBAuerbachBDChattarjiSBearMFCorrection of fragile X syndrome in miceNeuron20075695596218093519 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="266" pm="."><plain>104HuangHSAllenJAMabbAMKingIFMiriyalaJTaylor-BlakeBSciakyNDuttonJWJrLeeHMChenXJinJBridgesASZylkaMJRothBLPhilpotBDTopoisomerase inhibitors unsilence the dormant allele of Ube3a in neuronsNature2012481185189 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="267" pm="."><plain>105SmithDGEhlersMDMining and modeling human genetics for autism therapeuticsCurr Opin Neurobiol20122290291022483267 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="268" pm="."><plain>106SmithSEZhouYDZhangGJinZStoppelDCAndersonMPIncreased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in miceSci Transl Med20113103ra97 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="269" pm="."><plain>107SahinMTargeted treatment trials for tuberous sclerosis and autism: no longer a dreamCurr Opin Neurobiol20122289590122560338 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="270" pm="."><plain>108GregorySGConnellyJJTowersAJJohnsonJBiscochoDMarkunasCALintasCAbramsonRKWrightHHEllisPLangfordCFWorleyGDelongGRMurphySKCuccaroMLPersicoAPericak-VanceMAGenomic and epigenetic evidence for oxytocin receptor deficiency in autismBMC Med200976219845972 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="271" pm="."><plain>109WuSJiaMRuanYLiuJGuoYShuangMGongXZhangYYangXZhangDPositive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han populationBiol Psychiatry200558747715992526 </plain></SENT>
</text></ref><ref id="B110"><text><SENT sid="272" pm="."><plain>110TakayanagiYYoshidaMBielskyIFRossHEKawamataMOnakaTYanagisawaTKimuraTMatzukMMYoungLJNishimoriKPervasive social deficits, but normal parturition, in oxytocin receptor-deficient miceProc Natl Acad Sci U S A2005102160961610116249339 </plain></SENT>
</text></ref><ref id="B111"><text><SENT sid="273" pm="."><plain>111HigashidaHLopatinaOYoshiharaTPichuginaYASoumarokovAAMunesueTMinabeYKikuchiMOnoYKorshunovaNSalminaABOxytocin signal and social behaviour: comparison among adult and infant oxytocin, oxytocin receptor and CD38 gene knockout miceJ Neuroendocrinol20102237337920141571 </plain></SENT>
</text></ref><ref id="B112"><text><SENT sid="274" pm="."><plain>112YatawaraCJEinfeldSLHickieIBDavenportTAGuastellaAJThe effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trialMol Psychiatry2015 </plain></SENT>
</text></ref><ref id="B113"><text><SENT sid="275" pm="."><plain>113WatanabeTKurodaMKuwabaraHAokiYIwashiroNTatsunobuNTakaoHNippashiYKawakuboYKunimatsuAKasaiKYamasueHClinical and neural effects of six-week administration of oxytocin on core symptoms of autismBrain20151383400341226336909 </plain></SENT>
</text></ref><ref id="B114"><text><SENT sid="276" pm="."><plain>114GuastellaAJHickieIBOxytocin treatment, circuitry and autism: a critical review of the literature placing oxytocin into the autism contextBiol Psychiatry2015pii: S0006-3223(15)00543-0 </plain></SENT>
</text></ref><ref id="B115"><text><SENT sid="277" pm="."><plain>115BuxbaumJDDalyMJDevlinBLehnerTRoederKStateMWAutism Sequencing ConsortiumThe autism sequencing consortium: large-scale, high-throughput sequencing in autism spectrum disordersNeuron2012761052105623259942 </plain></SENT>
</text></ref><ref id="B116"><text><SENT sid="278" pm="."><plain>116ButlerMGRafiSKHossainWStephanDAManzardoAMWhole exome sequencing in females with autism implicates novel and candidate genesInt J Mol Sci2015161312133525574603 </plain></SENT>
</text></ref><ref id="B117"><text><SENT sid="279" pm="."><plain>117ChapmanNHNatoAQJrBernierRAnkenmanKSohiHMunsonJPatowaryAArcherMBlueEMWebbSJCoonHRaskindWHBrkanacZWijsmanEMWhole exome sequencing in extended families with autism spectrum disorder implicates four candidate genesHum Genet20151341055106826204995 </plain></SENT>
</text></ref><ref id="B118"><text><SENT sid="280" pm="."><plain>118Moreno-RamosOAOlivaresAMHaiderNBde AutismoLCLattigMCWhole-Exome Sequencing in a South American Cohort Links ALDH1A3, FOXN1 and Retinoic Acid Regulation Pathways to Autism Spectrum DisordersPLoS One201510e013592726352270 </plain></SENT>
</text></ref><ref id="B119"><text><SENT sid="281" pm="."><plain>119TammimiesKMarshallCRWalkerSKaurGThiruvahindrapuramBLionelACYuenRKUddinMRobertsWWeksbergRWoodbury-SmithMZwaigenbaumLAnagnostouEWangZWeiJHoweJLGazzelloneMJLauLSungWWWhittenKVardyCCrosbieVTsangBD'AbateLTongWWLuscombeSDoyleTCarterMTSzatmariPStucklessSMericoDStavropoulosDJSchererSWFernandezBAMolecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorderJAMA201531489590326325558 </plain></SENT>
</text></ref><ref id="B120"><text><SENT sid="282" pm="."><plain>120KoukouiSDChaudhuriANeuroanatomical, molecular genetic, and behavioral correlates of fragile X syndromeBrain Res Rev200753273816844227 </plain></SENT>
</text></ref><ref id="B121"><text><SENT sid="283" pm="."><plain>121CuratoloPPorfirioMCManziBSeriSAutism in tuberous sclerosisEur J Paediatr Neurol2004832733215542389 </plain></SENT>
</text></ref><ref id="B122"><text><SENT sid="284" pm="."><plain>122GargSLehtonenAHusonSMEmsleyRTrumpDEvansDGGreenJAutism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based studyDev Med Child Neurol20135513914523163236 </plain></SENT>
</text></ref><ref id="B123"><text><SENT sid="285" pm="."><plain>123MossJHowlinPMagiatiIOliverCCharacteristics of autism spectrum disorder in Cornelia de Lange syndromeJ Child Psychol Psychiatry20125388389122490014 </plain></SENT>
</text></ref><ref id="B124"><text><SENT sid="286" pm="."><plain>124HowlinPKarpfJTurkJBehavioural characteristics and autistic features in individuals with Cohen SyndromeEur Child Adolesc Psychiatry200514576415793684 </plain></SENT>
</text></ref><ref id="B125"><text><SENT sid="287" pm="."><plain>125SplawskiIYooDSStotzSCCherryAClaphamDEKeatingMTCACNA1H mutations in autism spectrum disordersJ Biol Chem2006281220852209116754686 </plain></SENT>
</text></ref><ref id="B126"><text><SENT sid="288" pm="."><plain>126BukelisIPorterFDZimmermanAWTierneyESmith-Lemli-Opitz syndrome and autism spectrum disorderAm J Psychiatry20071641655166117974928 </plain></SENT>
</text></ref><ref id="B127"><text><SENT sid="289" pm="."><plain>127TordjmanSAndersonGMBotbolMToutainASardaPCarlierMSaugier-VeberPBaumannCCohenDLagneauxCTabetACVerloesAAutistic disorder in patients with Williams-Beuren syndrome: a reconsideration of the Williams-Beuren syndrome phenotypePLoS One20127e3077822412832 </plain></SENT>
</text></ref><ref id="B128"><text><SENT sid="290" pm="."><plain>128KoochekMHarvardCHildebrandMJVan AllenMWingertHMickelsonEHoldenJJRajcan-SeparovicELewisME15q duplication associated with autism in a multiplex family with a familial cryptic translocation t(14;15) (q11.2;q13.3) detected using array-CGHClin Genet20066912413416433693 </plain></SENT>
</text></ref><ref id="B129"><text><SENT sid="291" pm="."><plain>129LajeGMorseRRichterWBallJPaoMSmithACAutism spectrum features in Smith-Magenis syndromeAm J Med Genet C Semin Med Genet2010154C45646220981775 </plain></SENT>
</text></ref><ref id="B130"><text><SENT sid="292" pm="."><plain>130Lo-CastroAGalassoCCerminaraCEl-MalhanyNBenedettiSNardoneAMCuratoloPAssociation of syndromic mental retardation and autism with 22q11.2 duplicationNeuropediatrics20094013714020020400 </plain></SENT>
</text></ref><ref id="B131"><text><SENT sid="293" pm="."><plain>131RadoevaPDComanILSalazarCAGentileKLHigginsAMMiddletonFAAntshelKMFremontWShprintzenRJMorrowBEKatesWRAssociation between autism spectrum disorder in individuals with velocardiofacial (22q11.2 deletion) syndrome and PRODH and COMT genotypesPsychiatr Genet20142426927225325218 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Molecular pathways implicated in neurodevelopmental disorders. RTKs, receptor tyrosine kinases; iGluRs, metabotropic glutamate receptors; PGC-1Î±, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; SREBP, sterol regulatory element-binding proteins; HIF1Î±, hypoxia-inducible factor 1 alpha; ULK1, unc-51-like kinase 1; ARC, activity-regulated cytoskeleton-associated protein; UBE3A, ubiquitin protein ligase E3A; MeCP2, methyl CpG binding protein 2; FMRP, fragile X mental retardation protein; PI3K/mTOR , phosphatidylinositol 3-kinase/mammalian target of rapamycin; PSD-95, postsynaptic density protein 95; CNTNAP2, Contactin-associated protein-like 2; NF1, neurofibromin 1; PLCÎ², Abstract Phospholipase C Î²; SYNGAP1, Synaptic Ras GTPase-activating protein 1; ERK1/2, extracellular signal-regulated kinase; PTEN, Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase; PDK1, Pyruvate dehydrogenase lipoamide kinase isozyme 1; PKC, Paroxysmal kinesogenic choreoathetosis, neurological disorder Protein kinase C; AKT, Protein kinase B; AMPK, AMP-activated protein kinase; TSC2, Tuberous Sclerosis Complex 2; TSC1, tuberous sclerosis 1; RHEB, GTP-binding protein Rheb; DEPDC5, DEP domain-containing 5; mTORC1, mammalian target of rapamycin complex 1; mGluR, metabotropic glutamate receptor; SHANK, Shank protein; ATG13, Autophagy-related protein 13; HDAC, Histone deacetylases; CHD8, Chromodomain-helicase-DNA-binding protein 8; MEF2, myocyte enhancer factor-2; RAS, Ras protein; TBC1D7, TBC1 domain family, Member 7; 4E-BPs, eIF4E-binding proteins; FIP200, a ULK-interacting protein; S6K1/2, Anti-RIBOSOMAL S6 KINASE 1/2; HOMER, homer scaffolding protein; RAGA/B, Ras-related GTP binding A/B ortholog; RAGC/D, Ras-related GTP binding C/D ortholog. From M. Sahin and M. Sur, Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders, Science 350, aab3897 (2015). DOI: 10.1126/science.aab3897. Reprinted with permission from The American Association for the Advancement of Science (AAAS).</title></caption><graphic xlink:href="en-24-257-g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Examples of monogenic "syndromic" autism and related phenotypes</title></caption><graphic xlink:href="en-24-257-i001"/><table-wrap-foot><fn><p>ASD, autism spectrum disorder.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
